-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
First API Approval of the Year! Guangxiang Pharmaceutical of Shijiazhuang Sihua Pharmaceutical Group Receives Marketing Authorization for Benidipine Hydrochloride API
Category:
发布时间：2025-01-07
【概要描述】
At the start of the new year, on January 6, the benidipine hydrochloride API submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved for “A” classification, making it the group’s first newly approved API product in 2025.
At the start of the new year, on January 6, the benidipine hydrochloride API submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Sihua Pharmaceutical Group, was approved for “A” classification, making it the group’s first newly approved API product in 2025.
To date, the Group has received approval for a total of 68 active pharmaceutical ingredient (API) products, with Guangxiang Pharmaceutical accounting for 38 of these approvals.
According to available information, benidipine hydrochloride API is a calcium channel blocker primarily indicated for the treatment of primary hypertension and angina pectoris. The approval of this product as an API for marketed dosage forms will further expand the Group’s portfolio of specialty APIs and support the deeper integration of “APIs plus formulations” across the value chain.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091